Protective effects of Guizhi-Fuling-Capsules on rat brain ischemia/reperfusion injury.
Previous studies revealed that Guizhi-Fuling-Capsules (GZFLC), a traditional Chinese medical (Kampo) formulation composed of five kinds of medicinal plants, Cinnamomum cassia BLUME (Cinnamomi Cortex), Paeonia lactiflora PALL. (Peonies Radix), Paeonia suffruticosa ANDREWS (Moutan Cortex), Prunus persica BATSCH (Persicae Semen), and Poria cocos WOLF (Hoelen), exerts a protective effect against vascular injury and has a protective effect against glutamate- or nitro oxide-mediated neuronal damage. In the present study, the effect of GZFLC in a rat in vivo model of focal cerebral ischemia and reperfusion was investigated. Administration of GZFLC (0.3 and 0.9 g/kg, p.o.) after focal cerebral ischemia significantly decreased brain infarction and water contents in rats subjected to 2-h ischemia followed by 24-h reperfusion from 31.72 +/- 2.49%, 84.76 +/- 1.63% in the model group to 17.31 +/- 3.66%, 82.51 +/- 1.36% and 8.30 +/- 3.73%, 81.35 +/- 1.73%, respectively. Furthermore, analysis of inflammatory cytokines in ischemic brain showed that GZFLC treatment significantly down-regulated expressions of pro-inflammatory cytokines including interleukin (IL)-1beta and tissue necrosis factor-alpha and markedly up-regulated expressions of anti-inflammatory cytokines IL-10 and IL-10R both in mRNA and protein levels. The serum levels of these inflammatory cytokines were also regulated the same way. These results suggested that GZFLC may be beneficial for the treatment of brain ischemia-reperfusion injury partly due to its anti-inflammatory properties.
Li
Tie-Jun
TJ
Department of Pharmacology, School of Pharmacy, Second Military Medical University, 325 GuoHe Road, Shanghai 200433, China.
Qiu
Yan
Y
Mao
Jun-Qin
JQ
Yang
Peng-Yuan
PY
Rui
Yao-Cheng
YC
Chen
Wan-Sheng
WS
D000818:Animals; D015153:Blotting, Western; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001923:Brain Chemistry / Q000187:drug effects; D001930:Brain Injuries / Q000209:etiology / Q000517:prevention & control*; D002214:Capsules; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal; D007091:Image Processing, Computer-Assisted / Q000379:methods; D018836:Inflammation Mediators / Q000097:blood / Q000378:metabolism; D016753:Interleukin-10 / Q000097:blood / Q000235:genetics / Q000378:metabolism; D053583:Interleukin-1beta / Q000097:blood / Q000235:genetics / Q000378:metabolism; D008297:Male; D008516:Medicine, Chinese Traditional; D020835:Medicine, Kampo; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D053701:Receptors, Interleukin-10 / Q000097:blood / Q000235:genetics / Q000378:metabolism; D015427:Reperfusion Injury / Q000150:complications / Q000517:prevention & control*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects
D002214:Capsules; D004365:Drugs, Chinese Herbal; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D010936:Plant Extracts; D012333:RNA, Messenger; D053701:Receptors, Interleukin-10; D014409:Tumor Necrosis Factor-alpha; C525079:guizhi-fuling; D016753:Interleukin-10